SequelSEC

Arcadia Biosciences, Inc. RKDA

Crude Petroleum & Natural Gas · CIK 0001469443 · Fiscal year ends 1231

Revenue
$4.86M
Fiscal year ended 2025-12-31
Operating income
-$2.50M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Arcadia Biosciences, Inc. (RKDA) reported revenue of $4.86M and net income of -$2.34M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Arcadia Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Crude Petroleum & Natural Gas.

Income

Arcadia Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$4.86M$5.04M$4.45M$7.42M$6.78M$8.03M$1.17M$1.46M$4.03M$3.19M
Cost of revenue$3.10M$2.96M$2.17M$6.10M$8.71M$5.20MUnavailableUnavailable$283.00K$895.00K
Gross profit$1.76M$2.08M$2.28M$1.32M-$1.93M$2.84MUnavailableUnavailableUnavailable$2.29M
Operating income-$2.50M-$3.65M-$6.10M-$14.01M-$35.53M-$12.78M-$19.38M-$16.87M-$14.32M-$18.62M
Net income-$2.34M-$7.04M-$13.98M-$15.38M-$14.66M-$4.66M-$28.80M-$13.48M-$15.71M-$19.62M
Research & development$9.00K$53.00K$64.00K$1.51M$3.89M$7.96M$7.10M$6.07M$7.41M$8.66M
Weighted-average diluted sharesshares 1.37Mshares 1.36Mshares 1.24MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$2.33M-$4.31M-$5.32M-$10.81M-$16.13M-$6.15M-$28.87M-$13.47M-$15.68M-$19.60M
Income tax expense$8.00K$8.00K$8.00K$14.00K$2.00K-$124.00K$2.00K$10.00K$26.00K$25.00K
Diluted EPS$-1.71$-5.17$-11.29$-25.65$-27.56UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$7.00M$9.64M$8.23M$15.04M$22.94M$16.47M$13.57M$11.60M$10.65M$12.25M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Arcadia Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$259.00K$4.24M$6.52M$20.64M$28.68M$14.04M$8.42M$12.00M$9.12M$2.01M
Total assets$6.55M$13.52M$19.70M$28.92M$43.92M$47.35M$32.57M$24.02M$16.57M$56.57M
Current assets$6.36M$9.24M$14.97M$25.40M$35.39M$31.70M$28.44M$22.88M$15.05M$52.22M
Total liabilities$2.41M$7.29M$7.00M$8.02M$12.72M$18.80M$24.25M$11.21M$8.56M$34.38M
Current liabilities$2.06M$2.56M$3.59M$4.21M$5.04M$6.31M$5.71M$3.05M$3.52M$3.13M
Total equity incl. NCI$4.14M$6.22M$12.70M$20.90M$31.20M$28.55M$8.32M$12.82M$8.01M$22.20M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$1.21M$904.00K$837.00K$2.32M$4.43M$3.81M$1.79M$181.00K$229.00K$252.00K
Accounts receivableUnavailableUnavailableUnavailableUnavailable$1.37M$1.41M$602.00K$165.00K$1.23M$349.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable$408.00KUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable$0$2.10M$107.00K$0$0$25.13M
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Arcadia Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$4.70M-$9.63M-$15.29M-$13.98M-$25.87M-$30.22M-$17.20M-$13.63M-$13.96MUnavailable
Capital expenditures$0$16.00K$5.00K$72.00K$1.01M$2.34M$1.48M$250.00K$79.00K$231.00K
Investing cash flow$750.00K$7.34M-$4.34M$1.42M$16.61M$17.28M-$8.37M-$5.98M$47.18MUnavailable
Financing cash flow$6.00K$9.00K$5.51M$4.52M$21.90M$20.56M$21.99M$22.48M-$26.10MUnavailable
Net change in cash-$3.98M-$2.28M-$14.13M-$8.04M$12.64M$7.63M-$3.58M$2.87M$7.11M-$21.96M
Stock-based compensation$234.00K$512.00K$717.00K$1.11M$1.54M$2.04M$2.29M$1.55M$1.47M$1.06M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$154.00K$279.00K$304.00K

Derived

Arcadia Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailable-$9.64M-$15.30M-$14.05M-$26.88M-$32.55M-$18.68M-$13.88M-$14.04MUnavailable
Gross margin36.2%41.3%51.2%17.8%-28.4%35.3%UnavailableUnavailableUnavailable71.9%
Operating margin-51.5%-72.3%-137.0%-188.8%-524.0%-159.0%-1657.9%-1152.3%-355.6%-584.1%
FCF marginUnavailable-191.1%-343.5%-189.4%-396.4%-405.2%-1597.5%-948.2%-348.8%Unavailable
SBC / revenue4.8%10.1%16.1%14.9%22.7%25.4%195.6%105.9%36.6%33.2%
Current ratio3.09x3.61x4.17x6.03x7.02x5.02x4.98x7.49x4.27x16.69x
Revenue YoY growth-3.7%13.3%-40.0%9.4%-15.6%587.3%-20.2%-63.6%26.3%Unavailable
Net margin-48.1%-139.5%-313.9%-207.3%-216.2%-57.9%-2464.1%-920.8%-390.1%-615.6%
R&D / revenue0.2%1.1%1.4%20.3%57.4%99.1%607.2%414.5%184.0%271.7%
CapEx / revenue0.0%0.3%0.1%1.0%14.9%29.1%126.3%17.1%2.0%7.2%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RKDA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K/A · Filed 2026-04-30View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-14View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2017-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.